Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 5, 2007

View Archived Issues

Novel candidate gene for Parkinson's disease identified

Treatment option for opioid dependency imparted in recent Reckitt Benckiser patent

New coagulation factor VIIa inhibitors disclosed in recent Eisai patent

Recent GSK and Mochida patents report novel analgesic agents

Studies detail efficacy of sugammadex in reversing neuromuscular blockade

DTS-201 safe in first-in-man study

In vivo antinociceptive effects reported for novel alpha2-adrenoceptor agonist

New gene associated with cardiovascular disease identified

Novel compounds overcome drug resistance in tumors expressing BCRP

Preclinical and clinical profile of BIIB-021, an Hsp90 inhibitor with antitumor activity

Antitumor effects seen with JX-594 in patients with liver tumors

MGCD-0103 and gemcitabine given in combination to patients with solid tumors

Santhera reports positive results from phase IIa trial of SNT-MC17

Ono and Medarex file IND for MDX-1106/ONO-4538 for hepatitis C

Eisai delays filing of regulatory submission of E-2007 until the fourth quarter of 2008

Cytokine reports oral efficacy of anti-cytokine semapimod

Taisho and Pfizer sign letter of intent for schizophrenia drug candidate

Tranzyme initiates phase IIb TZP-101 trial for severe gastroparesis

Lev amends Cinryze BLA for the treatment of hereditary angioedema

Vanda presents top-line results of phase II trial of VSF-173 for excessive sleepiness

Clinuvel initiates phase II trials of CUV-1647 for sun damage and actinic keratosis

Addrenex and Sciele initiate phase III trials for Clonicel

Enzon initiates phase I study of EZN-2968 to evaluate additional dosing schedule

Neoprobe and FDA agree on design of phase III trials for Lymphoseek

BioLineRx presents positive results from phase IIa interim trial of BL-1020 for schizophrenia

FDA accepts Indevus Pharmaceuticals' NDA for Nebido for male hypogonadism

FDA issues a not approvable letter for gepirone extended-release tablets

Trophos reports clinical results for TRO-19622 in patients with ALS

First U.S. clinical results for Avigen's antispastic agent AV-650

Noninvasive NGF-based therapies for Alzheimer's disease described by Italian investigators

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 28, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 28, 2026.
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Muted and missing M&As: JPM deals absent in 2026
BioWorld
For years, the J.P. Morgan Healthcare Conference (JPM) kicked off with splashy headlines of major M&A activity among biopharma companies, but in 2026, the hype...